Development and evaluation of inhalable particles containing kanamycin monosulphate and pyrazinoic acid for the treatment of drug resistant tuberculosis

dc.contributor.guide	Amit Misra
dc.coverage.spatial
dc.creator.researcher	Ashish Shrivastava
dc.date.accessioned	2022-06-17T09:27:07Z
dc.date.available	2022-06-17T09:27:07Z
dc.date.awarded	2019
dc.date.completed	2019
dc.date.registered	2015
dc.description.abstract	newline
dc.description.note
dc.format.accompanyingmaterial	None
dc.format.dimensions
dc.format.extent	All Pages
dc.identifier.uri	http://hdl.handle.net/10603/387021
dc.language	English
dc.publisher.institution	Biological Sciences (CSIR-CDRI)
dc.publisher.place	Ghaziabad
dc.publisher.university	Academy of Scientific and Innovative Research (AcSIR)
dc.relation
dc.rights	university
dc.source.university	University
dc.subject.keyword	Biology
dc.subject.keyword	Biology and Biochemistry
dc.subject.keyword	Life Sciences
dc.title	Development and evaluation of inhalable particles containing kanamycin monosulphate and pyrazinoic acid for the treatment of drug resistant tuberculosis
dc.title.alternative
dc.type.degree	Ph.D.